What is Repligen's market cap?

Repligen (RGEN) has a market capitalization of $7.4B and trades on NASDAQ.

What is Repligen's revenue and profitability?

Repligen generated $769.6M in trailing twelve-month revenue with net income of $41.5M, representing a net margin of 17.3%. Gross margin stands at 47.6%, with free cash flow of $112.0M. These figures are based on the Q2 2026 filing.

Who are Repligen's competitors?

Repligen's key competitors include Danaher Corporation, Thermo Fisher Scientific, Alpha Teknova, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Repligen partner with?

Repligen's notable partners include Purolite, Navigo Proteins GmbH.

What subsidiaries does Repligen have?

Repligen's subsidiaries include Metenova, ARTeSYN Biosolutions, C Technologies, Inc., and others.

Where is Repligen headquartered?

Repligen is headquartered in United States of America and employs approximately 1,783 people. It has been publicly traded since 1986.

Repligen

RGEN

Repligen Corporation is a global life sciences company specializing in the development and commercialization of innovative bioprocessing technologies and systems.

Market cap

$7.39B+7.1%

Revenue$769.6M+22.3%

Net income$41.5M+400%

Free cash flow$112.0M+2.8%

EPS (diluted)$0.76+300%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 28, 2026

Revenue$204.1MBeat by $2.5M EPS$0.54Beat by $0.09

Read the full report

Next report

Oct 27, 2026 (in 3 months)

Revenue estimate$206.9M

EPS estimate$0.46

Financials

Q2 2026

Income statement

See full

Revenue$204.1M+11.9%

Gross profit$110.0M+20.7%

Operating income$14.0M+0.6%

Net income$5.0M-66.3%

EPS (diluted)$0.09-65.4%

Balance sheet

See full

Cash & equivalents$606.8M-14.4%

Total debt$690.9M+354%

Total equity$2.1B+2.4%

Total assets$3.0B+1.7%

Cash flow

See full

Operating cash flow$32.8M+14.5%

CapEx$5.3M-24.9%

Free cash flow$27.4M+27.5%

Valuation & ratios

Valuation

See full

Market cap$7.39B+7.1%

Enterprise value$7.48B+21.3%

P/E178×—

P/S9.6×—

Returns & leverage

See full

Return on equity2%+1.6pp

Debt / equity0.3×+0.3×

Current ratio9.1×+0.5×

Segments

By product

See full

Royalty$43.0K+16.2%

Competitors

By market cap

Thermo Fisher Scientific$207.93B+13.6%

Danaher$138.14B-4.9%

Revvity$12.1B+7.6%

Charles River Laboratories$10.8B+22.9%

Bio-Rad Laboratories$8.5B+22.9%

Repligen$7.4B+10.0%

Alpha Teknova, Inc.$260.0M-5.3%

Dyadic International$41.2M+23.3%

By revenue growth

Repligen+22.3%

Thermo Fisher Scientific+5.6%

Revvity+4.8%

Danaher+4.6%

Bio-Rad Laboratories+1.9%

Charles River Laboratories+0.1%

By net margin

Repligen17.29%+7.6pp

Danaher15.95%+1.7pp

Thermo Fisher Scientific15.19%0.0pp

Revvity8.26%-2.1pp

Bio-Rad Laboratories6.52%+91.7pp

Charles River Laboratories-4.59%-11.1pp

Profile

Repligen Corporation is a global life sciences company specializing in the development and commercialization of innovative bioprocessing technologies and systems. The company provides critical tools and consumables that increase efficiency, flexibility, and yield in the manufacturing of biological drugs, including monoclonal antibodies, vaccines, and cell and gene therapies. Its value proposition centers on solving production cost, capacity, and quality challenges for biopharmaceutical manufacturers through a comprehensive suite of upstream and downstream solutions.

Competitive position

A leading provider of single-use bioprocessing technologies with a dominant position in the pre-packed chromatography column and Protein A ligand markets.

GeographiesNorth America, Europe, Asia Pacific

Customer segmentsBiopharmaceutical companies, CDMOs, Life science integrators, Academic researchers

Business modelConsumables-based manufacturing, Direct sales, B2B supply agreements

SuppliersRaw material suppliers, Resin manufacturers, Specialized component providers, Contract manufacturers

CustomersGlobal biopharmaceutical firms, Contract Development and Manufacturing Organizations, Diagnostic companies, Laboratory researchers

CountryUnited States of America

Listed1986

Employees1.8K

CEOOlivier Loeillot

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websiterepligen.com

FilingsSEC EDGAR

Ask your AI about Repligen.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Repligen's market cap?: Repligen (RGEN) has a market capitalization of $7.4B and trades on NASDAQ.
What is Repligen's revenue and profitability?: Repligen generated $769.6M in trailing twelve-month revenue with net income of $41.5M, representing a net margin of 17.3%. Gross margin stands at 47.6%, with free cash flow of $112.0M. These figures are based on the Q2 2026 filing.
Who are Repligen's competitors?: Repligen's key competitors include Danaher Corporation, Thermo Fisher Scientific, Alpha Teknova, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Repligen partner with?: Repligen's notable partners include Purolite, Navigo Proteins GmbH.
What subsidiaries does Repligen have?: Repligen's subsidiaries include Metenova, ARTeSYN Biosolutions, C Technologies, Inc., and others.
Where is Repligen headquartered?: Repligen is headquartered in United States of America and employs approximately 1,783 people. It has been publicly traded since 1986.